These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31345074)

  • 81. Assessing bioresorbable coronary devices: methods and parameters.
    Garcia-Garcia HM; Serruys PW; Campos CM; Muramatsu T; Nakatani S; Zhang YJ; Onuma Y; Stone GW
    JACC Cardiovasc Imaging; 2014 Nov; 7(11):1130-48. PubMed ID: 25459595
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Onuma Y; Garcia-Garcia HM; Waksman R
    Eur Heart J; 2016 Sep; 37(35):2701-9. PubMed ID: 27190094
    [TBL] [Abstract][Full Text] [Related]  

  • 83. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial.
    Haude M; Erbel R; Erne P; Verheye S; Degen H; Böse D; Vermeersch P; Wijnbergen I; Weissman N; Prati F; Waksman R; Koolen J
    Lancet; 2013 Mar; 381(9869):836-44. PubMed ID: 23332165
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Evaluation of the MiStent sustained sirolimus eluting biodegradable polymer coated stent for the treatment of coronary artery disease: does uniform sustained abluminal drug release result in earlier strut coverage and better safety profile?
    Tijssen RYG; Kraak RP; Lu H; Mifek JG; Carlyle WC; Donohoe DJ; De Winter RJ; Koch KT; Wykrzykowska JJ
    Expert Rev Med Devices; 2017 May; 14(5):325-334. PubMed ID: 28402204
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Giniewicz K; Łanocha M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Włodarczak P; Doroszko A; Lesiak M
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793122
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 88. A review of bioresorbable scaffolds: hype or hope?
    Tan HC; Ananthakrishna R
    Singapore Med J; 2017 Sep; 58(9):512-515. PubMed ID: 27868135
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Technical overview on the MiStent coronary stent.
    McCLAIN JB; Carlyle WC; Donohoe DJ; Ormiston JA
    Minerva Cardioangiol; 2016 Oct; 64(5):560-71. PubMed ID: 27152624
    [TBL] [Abstract][Full Text] [Related]  

  • 90. A word of caution: Early failure of Magmaris® bioresorbable stent after pulmonary artery stenting.
    Haddad RN; Adel Hassan A; Al Soufi M; Kasem M
    Catheter Cardiovasc Interv; 2023 Jan; 101(1):131-134. PubMed ID: 36413609
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Looking into the future with bioresorbable vascular scaffolds.
    Costopoulos C; Naganuma T; Latib A; Colombo A
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1407-16. PubMed ID: 24138526
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Novel drug-eluting stents for coronary revascularization.
    Gogas BD; McDaniel M; Samady H; King SB
    Trends Cardiovasc Med; 2014 Oct; 24(7):305-13. PubMed ID: 25240980
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Endovascular Therapy for Infrainguinal Artery Disease With Coronary Devices: A Retrospective Observational Study Comparing Drug-Eluting Stents Versus Bioresorbable Vascular Scaffolds.
    Giordano A; Ferraro P; Corcione N; Messina S; Maresca G; Coscioni E; Avellino R; Giordano G; Peruzzi M; Biondi-Zoccai G
    Angiology; 2017 Jan; 68(1):59-66. PubMed ID: 26980773
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design.
    Woudstra P; Grundeken MJ; Kraak RP; Hassell ME; Arkenbout EK; Baan J; Vis MM; Koch KT; Tijssen JG; Piek JJ; de Winter RJ; Henriques JP; Wykrzykowska JJ
    Am Heart J; 2014 Feb; 167(2):133-40. PubMed ID: 24439973
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Bioresorbable Vascular Scaffold: A Focused Review on Development and Preclinical Studies].
    Ke L; Huang Y; Liu L; Duan X; Feng X; Wang C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Feb; 42(2):115-118. PubMed ID: 29845812
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A new resorbable magnesium scaffold (DREAMS 3G): 12-month vasomotion results from the BIOMAG-I first-in-human study.
    Haude M; Iglesias JF; Garcia-Garcia HM; Barlagiannis D; Degrauwe S; Melaku G; Beyene S; Waksman R
    EuroIntervention; 2024 Sep; 20(17):e1118-e1120. PubMed ID: 39219359
    [No Abstract]   [Full Text] [Related]  

  • 97. Current perspectives on bioresorbable scaffolds in coronary intervention and other fields.
    Wu X; Wu S; Kawashima H; Hara H; Ono M; Gao C; Wang R; Lunardi M; Sharif F; Wijns W; Serruys PW; Onuma Y
    Expert Rev Med Devices; 2021 Apr; 18(4):351-365. PubMed ID: 33739213
    [No Abstract]   [Full Text] [Related]  

  • 98. The drug-eluting resorbable magnesium vascular scaffold in complex coronary bifurcations: insights from an in vivo multimodality imaging study.
    Bennett J; Vanhaverbeke M; Vanden Driessche N; Hiltrop N; Adriaenssens T; Desmet W; Sinnaeve P; Dubois C
    EuroIntervention; 2018 Apr; 13(17):2036-2046. PubMed ID: 28741575
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.